- Home
- WLGS vs XBIO Comparison
WLGS vs XBIO Comparison
Compare WLGS & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLGS
- XBIO
- Stock Information
- Founded
- WLGS 1981
- XBIO N/A
- Country
- WLGS Hong Kong
- XBIO United States
- Employees
- WLGS N/A
- XBIO N/A
- Industry
- WLGS Engineering & Construction
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- WLGS Consumer Discretionary
- XBIO Health Care
- Exchange
- WLGS Nasdaq
- XBIO Nasdaq
- Market Cap
- WLGS 4.4M
- XBIO 4.2M
- IPO Year
- WLGS 2023
- XBIO N/A
- Fundamental
- Price
- WLGS $0.05
- XBIO $3.53
- Analyst Decision
- WLGS
- XBIO Hold
- Analyst Count
- WLGS 0
- XBIO 1
- Target Price
- WLGS N/A
- XBIO N/A
- AVG Volume (30 Days)
- WLGS 37.9M
- XBIO 169.6K
- Earning Date
- WLGS 08-14-2025
- XBIO 08-12-2025
- Dividend Yield
- WLGS N/A
- XBIO N/A
- EPS Growth
- WLGS N/A
- XBIO N/A
- EPS
- WLGS N/A
- XBIO N/A
- Revenue
- WLGS $3,951,649.00
- XBIO $2,582,728.00
- Revenue This Year
- WLGS N/A
- XBIO $14.23
- Revenue Next Year
- WLGS N/A
- XBIO $7.14
- P/E Ratio
- WLGS N/A
- XBIO N/A
- Revenue Growth
- WLGS N/A
- XBIO 5.63
- 52 Week Low
- WLGS $0.04
- XBIO $2.20
- 52 Week High
- WLGS $9.66
- XBIO $5.27
- Technical
- Relative Strength Index (RSI)
- WLGS 25.41
- XBIO 58.63
- Support Level
- WLGS $0.05
- XBIO $2.65
- Resistance Level
- WLGS $0.05
- XBIO $5.27
- Average True Range (ATR)
- WLGS 0.02
- XBIO 0.45
- MACD
- WLGS 0.01
- XBIO 0.09
- Stochastic Oscillator
- WLGS 3.27
- XBIO 33.61
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED. WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, water supply and sewage disposal systems, and site project management.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.